2005
DOI: 10.1016/j.ijrobp.2005.07.641
|View full text |Cite
|
Sign up to set email alerts
|

The Evaluation of Amifostine for Mucosal Protection in Advanced Loco-Regional Squamous Cell Carcinomas of the Head and Neck (SCCHN) Treated with Concurrent Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy (RT)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
12
0
3

Year Published

2006
2006
2012
2012

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 8 publications
(15 citation statements)
references
References 0 publications
0
12
0
3
Order By: Relevance
“…The infusion of 250 mg of amifostine 15 min prior to radiotherapy reduced the severity of oral mucositis in the experimental when compared to the control group, but the difference did not reach significant levels in one, non-blinded, non-placebo-controlled study [9]. Grade 3 oral mucositis was reduced when compared to historical controls (40 versus 70 %) in patients who received 500 mg amifostine within 1 h before radiotherapy [11]. Oral mucositis was significantly lower in severity at all 10 Gy increments except 60 Gy and over in patients who received 300 mg amifostine before radiotherapy when compared with historical controls [39].…”
Section: Head and Neck Chemoradiotherapy: Preventionmentioning
confidence: 88%
See 4 more Smart Citations
“…The infusion of 250 mg of amifostine 15 min prior to radiotherapy reduced the severity of oral mucositis in the experimental when compared to the control group, but the difference did not reach significant levels in one, non-blinded, non-placebo-controlled study [9]. Grade 3 oral mucositis was reduced when compared to historical controls (40 versus 70 %) in patients who received 500 mg amifostine within 1 h before radiotherapy [11]. Oral mucositis was significantly lower in severity at all 10 Gy increments except 60 Gy and over in patients who received 300 mg amifostine before radiotherapy when compared with historical controls [39].…”
Section: Head and Neck Chemoradiotherapy: Preventionmentioning
confidence: 88%
“…In patients undergoing chemoradiotherapy for head and neck cancer, eight articles were reviewed [4,5,7,9,11,29,30,39 ]. In all eight studies, amifostine was administered for prevention.…”
Section: Head and Neck Chemoradiotherapy: Preventionmentioning
confidence: 99%
See 3 more Smart Citations